• Beyond borders: unlocking value

    With double-digit revenue growth and a sharp rise in funds raised, the global biotechnology industry rebounded strongly this year. Find out more in our annual report.

  • Life sciences: preparing for big data and analytics

    Many life sciences organizations are not capturing and applying value from analytics in a meaningful way. Gain the edge by harnessing today’s big data insights.

  • Biotechnology in Europe

    This joint EuropaBio and EY report analyzes current tax, finance and regulatory regimes for the biotech sector in Europe and details country-specific guidelines and incentives.

  • Navigating the payer landscape

    A revolution is happening in health care, and it’s being led by payers. Progressions, our global pharmaceutical report, explores how companies are responding.

  • Working capital report - Cash on prescription

    Pharma saw improved working capital performance in 2013, but progress has not been sufficient to reverse deterioration of previous years. Our report explores.

  • Pharma/payer relationships: appetite for reconstruction

    In our latest blog post, we discuss insights from The Economist’s annual Pharma Summit and changes ahead for national health care systems.

  • Shaping your telehealth strategy

    Learn how the health care industry is leveraging telehealth technologies to lower costs, improve quality outcomes and enhance the patient experience.

  • Commercial excellence in pharma 3.0

    The pharmaceutical industry is navigating a profound transformation into what we call “Pharma 3.0.” We explore how companies are adapting their commercial models in response.

  • Strategic divestments drive value

    Selling assets and re-shaping portfolios can help global companies navigate uncertainty, maximize growth opportunities and create value for their stakeholders. Learn how.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:




Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY Life Sciences: Building a better working world

EY Life Sciences: Building a better working world

Empowered patients are demanding more. Big data and supply chains offer new challenges. EY has the vision to help solve the industry's most pressing issues.